Clostridioides difficile, or C. diff, is a gut bacterium that can cause severe diarrhoea and may return after antibiotic treatment. Restoring healthy gut microbes can cut that risk: the US Food and Drug Administration (FDA) approved Rebyota, a faecal microbiota product given rectally, in 2022, and Vowst, an oral capsule, in 2023, to prevent recurrence in adults.
C. difficile tends to take hold when antibiotics wipe out the normal mix of gut microbes, and in serious cases it causes life-threatening inflammation of the colon. For years doctors restored that mix with faecal microbiota transplants, giving stool from screened donors by colonoscopy, enema or capsule. Screening varied, and in 2019 the FDA issued a warning after two patients were infected with drug-resistant bacteria from donor stool and one died. Rebyota and Vowst are made and tested to a fixed standard. Both are approved only to prevent another episode after antibiotic treatment, not to treat an active infection.

